NASDAQ$OVID

Ovid Therapeutics Inc · Q2 2019 earnings

Q2 2019 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.34

Previous: -$0.53+35.8%

Revenue & EPS history

Ovid Therapeutics · Revenue · Quarterly

$0

Q1 2026-100%vs Q1 2025
Beat estimate in 9 of 11 quarters(82%)
ActualEstimate

Revenue by segment

Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020

  • License and other revenue
    $5.7M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2019

Historical avgQ2 2019

-0.5%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+3.6%

Avg return

30 days after

43%

15 / 35 earnings

Positive

+19.5%

Q2 2024

Best reaction

-26.9%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.9%-5.7%
Q4 2025+14.4%+26.9%+44.8%
Q3 2025-2.2%-3.7%+21.5%
Q1 2025-0.7%-6.2%-8.2%
Q4 2024+0.1%-11.4%-48.0%
Q2 2024+19.5%+33.7%+31.4%
Q1 2024+9.9%+4.3%+6.0%
Q4 2023-7.3%-11.0%+2.5%
Q3 2023-7.9%-4.8%-9.5%
Q2 2023-1.8%-0.6%+6.6%
Q1 2023-5.2%-2.5%+0.1%
Q4 2022+4.0%+13.0%+46.0%
Q3 2022+2.1%+11.1%+26.4%
Q2 2022+0.5%+2.3%-1.4%
Q1 2022-12.1%-22.3%-30.5%
Q4 2021-3.4%+0.3%+0.3%
Q3 2021-2.8%+0.8%-9.7%
Q2 2021-9.4%-13.1%-14.4%
Q1 2021+2.3%+6.9%+28.4%
Q4 2020+4.4%+9.0%-6.1%
Q3 2020+18.9%+19.1%-49.6%
Q2 2020-2.4%+4.3%-20.4%
Q1 2020-0.3%+10.6%+43.7%
Q4 2019-26.9%-31.5%-7.8%
Q3 2019-1.5%-6.5%+54.2%
Q2 2019-2.1%-5.2%+11.9%
Q1 2019-14.0%-20.1%-24.8%
Q4 2018-2.0%+1.0%-6.1%
Q3 2018-8.0%-7.9%-39.1%
Q2 2018+2.3%+8.8%-0.2%
Q1 2018+4.8%-1.9%-9.5%
Q4 2017-13.1%-11.4%+35.7%
Q3 2017+15.2%+20.4%+49.7%
Q2 2017-1.6%+2.8%+28.0%
Q1 2017+5.3%+0.4%-29.7%
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro